期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EGFR和ErbB2双重酪氨酸激酶抑制剂拉帕替尼二甲苯磺酸酯的研究进展 被引量：3

Advance in research for lapatinib,a dual inhibitor of EGFR and ErbB2 tyrosine kinase activity
下载PDF
导出
摘要 拉帕替尼是一种人源2型表皮生长因子受体(HER2)和表皮生长因子受体(EGFR)双重酪氨酸激酶抑制剂,与卡培他滨联用治疗女性HER2阳性的乳腺癌。我们利用MEDLINE进行关键词为拉帕替尼的文献检索,对其药理作用、药动学、临床疗效及安全性,药物相互作用等进行综述。 Lapatinib is a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 （HER2 or HER2/neu） and epidermal growth factor receptor （EGFR）. It is active in combination with capecitabine in treatment of women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. A literature search was conducted by MEDLINE using the key word lapatinib. Its pharmacology, pharmacokinetics, efficacy, safety and drug interactions in the treatment of breast cancer are reviewed in this paper.
作者 封宇飞 曾春兰
机构地区 卫生部北京医院药学部临床药理室 广西工业职业技术学院
出处 《中国新药杂志》 CAS CSCD 北大核心 2007年第23期1990-1993,共4页 Chinese Journal of New Drugs
关键词 拉帕替尼二甲苯磺酸酯 酪氨酸激酶抑制剂 乳腺癌 lapatinib ditosylate tyrosine kinase inhibitor breast cancer
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献11

  • 1MOY B, GOSS PE. Lapatinib: current status and future directions in breast cancer [ J ]. Oncologist, 2006,11 ( 10 ) : 1047 - 1057.
  • 2NELSON MH, DOLDER CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors[J]. Ann Pharmacother, 2006,40 (2) :261 - 269.
  • 3MONTEMURRO F, VALABREGA G, AGLIETTA M. Lapatinib: a dual inhihitor of EGFR and HER2 tyrosine kinase activity [ J ]. Expert Opin Biol Ther, 2007,7 (2) :257 - 268.
  • 4FDA. TYKERB [ EB/OL]. [ 2007 - 07 - 16 ]. http://www. fda. gov/cder/foi/label/2007/022059s0011bl, pdf.
  • 5RUSNAK DW, AFFLECK K, COCKERILL SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitots: potential therapy for cancer [ J ]. Cancer Res, 2001,61 (19) :7196 -7203.
  • 6WOOD ER, TRUESDALE AT, MCDONALD OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) : relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells [ J ]. Cancer Res, 2004,64 ( 18 ) :6652 - 6659.
  • 7任晓岚,汪鑫,李志裕,尤启冬.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的研究进展[J].中国新药杂志,2005,14(7):821-826. 被引量：31
  • 8郭晓宁,林莉萍,章雄文,丁健.表皮生长因子受体酪氨酸激酶家族与肿瘤治疗[J].中国新药杂志,2005,14(10):1136-1140. 被引量：8
  • 9BENCE AK, ANDERSON EB, HALEPOTA MA, et al. Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects[J]. Invest New Drugs, 2005,23(1) :39 -49.
  • 10BURRIS HA, HURWITZ HI, DEES EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J]. J Clin Oncol, 2005, 23 (23): 5305 - 5313.

二级参考文献65

  • 1吴一龙.肺癌分子靶向治疗的个体化[J].循证医学,2004,4(2):67-68. 被引量：9
  • 2[1]Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy[ J]. Oncogene, 2000,19(56) :6550 - 6565.
  • 3[2]Yarden Y,Sliwkowski MX. Untangling the ErbB signaling network[ J ]. Nat Rev Mol Cell Biol,2001,2(2): 127 - 137.
  • 4[3]Normanno N, Maiello MR, de Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) :simple drugs with a complex mechanism of action? [J]. J Cell Physiol, 2003, 194( 1 ):13 - 19.
  • 5[4]Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression[J]. Exp Cell Res ,2003,284(1) :99 - 110.
  • 6[5]Graus Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all erbB receptors, is a mediator of lateral signaling[J]. EMBO J, 1997,16(7): 1647 - 1655.
  • 7[6]Zvibel J, Brill S, Halpern Z, et al. Soluble and matrix-associated heparan sulfate proteoglycans increase expression of ErbB-2 and ErbB-3 in colon cancer cell lines[J]. Int J Cancer, 2001,91 (3) :316 -321.
  • 8[7]Crovello CS,Lai C, Cantley LC, et al. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2 [ J ]. J Biol Chem, 1998,273 (41 ): 26954 - 26961.
  • 9[8]Gamett DC, Pearson G, Cerione RA, et al. Secondary dimerization between members of the epidermal growth factor receptor family[J]. J Biol Chem, 1997,272(18): 12052 - 12056.
  • 10[9]Zhang P, Wang YZ, Kagan E, et al. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate M APK[ J]. J Biol Chem, 2000,275 (29) :22479 - 22486.

共引文献36

同被引文献12

引证文献3

二级引证文献6

中国新药杂志
2007年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部